Tremelimumab + Durvalumab
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
EGFR Mutant Advanced Non Small Cell Lung Cancer
Conditions
EGFR Mutant Advanced Non Small Cell Lung Cancer
Trial Timeline
Oct 23, 2018 → Jan 31, 2024
NCT ID
NCT03994393About Tremelimumab + Durvalumab
Tremelimumab + Durvalumab is a phase 2 stage product being developed by AstraZeneca for EGFR Mutant Advanced Non Small Cell Lung Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT03994393. Target conditions include EGFR Mutant Advanced Non Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06526104 | Phase 2 | Recruiting |
| NCT04522544 | Phase 2 | Recruiting |
| NCT03994393 | Phase 2 | UNKNOWN |
| NCT03482102 | Phase 2 | Recruiting |
| NCT03075527 | Phase 2 | Terminated |
| NCT02870920 | Phase 2 | Completed |
Competing Products
20 competing products in EGFR Mutant Advanced Non Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH25448 | Yuhan | Phase 1/2 | 41 |
| YH32364 | Yuhan | Phase 1/2 | 41 |
| Datopotamab deruxtecan | Daiichi Sankyo | Pre-clinical | 23 |
| HER3-DXd | Daiichi Sankyo | Pre-clinical | 23 |
| ASP8273 | Astellas Pharma | Phase 2 | 52 |
| radio-labeled naquotinib + naquotinib | Astellas Pharma | Phase 1 | 33 |
| erlotinib | Astellas Pharma | Phase 1 | 33 |
| ASP8273 Capsules + ASP8273 Capsules A | Astellas Pharma | Phase 2 | 52 |
| famitinib po + HS-10296 po | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABT-414 | AbbVie | Pre-clinical | 23 |
| AZD9291 40 mg + AZD9291 80 mg | AstraZeneca | Phase 1 | 33 |
| Osimertinib-based adaptive treatment + Osimertinib 80 MG | AstraZeneca | Phase 2 | 52 |
| AZD9291 + MEDI4736 | AstraZeneca | Phase 3 | 77 |
| EGFR TKIs (gefitinib, erlotinib, afatinib, et al) | AstraZeneca | Pre-clinical | 23 |
| AZD9291 | AstraZeneca | Pre-clinical | 23 |
| Osimertinib | AstraZeneca | Phase 2 | 52 |
| Dasatinib + Osimertinib | AstraZeneca | Phase 1/2 | 41 |
| AZD9291 80mg oral each day | AstraZeneca | Phase 3 | 77 |
| Osimertinib | AstraZeneca | Phase 2 | 52 |
| AZD3759 + AZD9291 | AstraZeneca | Phase 1 | 33 |